MeiHua to acquire amino acid and HMO businesses of Kyowa Hakko Bio from Kirin for JPY10.5bn.

MeiHua, a China-based high-tech company centered on synthetic biology technology, agreed to acquire amino acid and HMO businesses of Kyowa Hakko Bio, a Japanese biotechnology and amino acids fermentation company, from Kirin, a Japanese beer and beverage holding company, for JPY10.5bn.